Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The oral Wegovy pill is bringing new patients into the GLP-1 fold. Since its January 2026 launch, oral semaglutide surpassed 100,000 new monthly prescriptions within just two months — faster than any injectable GLP-1 before it. Crucially, injectable prescriptions didn't drop, meaning the pill is expanding the overall market rather than cannibalizing existing users.
The Wegovy pill is growing the GLP-1 market — not just reshuffling it
When the FDA approved oral semaglutide (Wegovy pill, Novo Nordisk) for obesity at the end of 2025, the big question was: would it pull patients away from injectables, or bring in entirely new ones? A new study published in Annals of Internal Medicine has a clear answer — it's mostly the latter.
Researchers from Johns Hopkins analyzed national prescription data from July 2020 through June 2026. They found that the oral pill hit 100,000 new monthly prescriptions within just two months of its January 2026 launch — a pace far outstripping both injectable semaglutide and tirzepatide. Meanwhile, injectable prescriptions kept climbing, suggesting the pill is expanding the pool of GLP-1 users rather than replacing injections. Experts point to needle aversion, increasing social acceptance of weight-loss medications, and broader accessibility as key drivers of the pill's rapid uptake.
By the Numbers
Why it matters: The oral GLP-1 option is reaching patients who previously wouldn't have considered weight-loss medication — particularly those with injection aversion — potentially accelerating the already-booming obesity treatment landscape.
